Horama

Please note: The information displayed on this page might be outdated.
Horama: HORAMA develops new gene therapies for rare inherited ocular diseases and CNS diseases . HORAMA’s approach is based on vector technology using non-pathogenic, recombinant adeno-associated viruses (rAAV) and new generation of modified rAAV (mrAAV). The company's lead candidate is HORA-PDE6B, which is in Phase I/II clinical trials with an indication in PDE6B retinitis pigmentosa.

The company raised EUR 22.5 million of Series B venture funding from Kurma Partners, Pontifax Venture Capital, Fund+ on November 8, 2017. V-Bio, Turenne Capital, IdInvest Partners, GO Capital, Sham Innovation Santé and Omnes Capital also participated in the round.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Ophthalmology, Rare Disease
Industry
Biotechnology
Listing
Private
Market Cap
100MM - 500MM
Therapeutic Modalities
Cell Therapy, Gene Therapy
Website:
Profiles:
Address:
27 rue du Faubourg Saint-Jacques
Paris, Ile-de-France 75014
France

Company Participants at European Biotech Investor Day 2020

  • Christine Placet, CEO
  • Rodolphe Clerval, Chief Business Officer